Loading
A phase 2 trial of Avutometinib (VS-6766) + Defactinib (VS-6063) in ovarian cancer, run by Verastem, Inc., active and no longer recruiting.
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients is a phase 2 interventional study registered as NCT06682572 by Verastem, Inc., with 16 participants enrolled, started 2024-10-30 and due to reach its primary completion in 2025-12. Interventions recorded: Avutometinib (VS-6766) + Defactinib (VS-6063).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/